Some interesting things in here:
1. Additional benefits of afamelanotide treatment in EPP patients include hepatoprotection and maintenance of circadian rhythm. This builds a bigger moat for Scenesse against any future competitor drugs.
2. Stroke - "The next studies are already being prepared, taking into account the learnings from the clinical observations and learnings from CUV801." Sounds pretty positive.
On the downside, the comments regarding seasonality of Scenesse prescription and covid effects might be preparing us for a muted quarterly revenue report. This doesn't particularly concern me as they also mention PA submissions and/or renewals are already ramping up ahead of the northern hemisphere spring and summer seasons.
Ann: CLINUVEL Newsletter I - January 22, page-2
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.70 |
Change
0.120(0.88%) |
Mkt cap ! $685.8M | |||
| Open | High | Low | Value | Volume |
| $13.53 | $13.76 | $13.42 | $747.9K | 54.81K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 233 | $13.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.71 | 19 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |